By Fidelis Onode

A new biomedical investigation is offering fresh insight into one of cancer biology’s most persistent puzzles: how mechanical stress and metabolic conditions inside breast tumors work together to influence disease progression. Although cancer is often studied through genetic or biochemical lenses, researchers are increasingly discovering that the physical environment surrounding tumor cells plays a powerful and underappreciated role.

This interplay—long overlooked in common laboratory models—may help explain why certain breast cancers evolve more aggressively, evade immune defenses, and metastasize with alarming speed. At the heart of this study is the glycocalyx, a sugar-rich molecular coating that envelops all mammalian cells. Traditionally viewed as a biochemical antenna that interprets signals from the microenvironment, the glycocalyx is now emerging as a key mediator of mechanotransduction, the process by which cells sense and respond to physical forces.

This shift in understanding has opened new avenues for examining how mechanical stress and nutrient availability combine to reprogram cancer cell behavior. At the forefront of the research is Toheeb Alao, an expert biomedical engineering researcher at the New Jersey Institute of Technology whose work sits squarely at the intersection of mechanobiology, glycocalyx regulation, and cancer metabolism.

Trained in advanced molecular engineering and imaging techniques, he has conducted research on mechanoresponsive glycosylation pathways and co-authored peer-reviewed work examining how sialylation influences cancer cell mechanics—a foundation that directly informs the current investigation. His expertise with CRISPR-based gene manipulation, RNA-sequencing, and physiologically relevant hydrogel models positions him to help dissect how physical forces and metabolic cues jointly shape breast tumor behavior.

The research is particularly focused on how extracellular matrix (ECM) stiffness—which increases as tumors progress—interacts with physiological glucose levels to regulate sialyltransferases (STs), enzymes that add sialic acid molecules to the cell surface. These additions influence how cancer cells move, adhere, and communicate with the immune system. Previous studies have shown that many breast cancers become “hypersialylated,” cloaking themselves from immune detection and acquiring properties that facilitate metastasis.

Early findings reveal a striking pattern: under normal glucose concentrations that resemble human blood—not the artificially high levels used in conventional cell culture—only two enzymes, ST6GALNAC4 and ST6GALNAC6, respond reliably to increasing matrix stiffness. This suggests that these enzymes function as “mechano-metabolic sensors”, potentially driving epithelial-to-mesenchymal transition (EMT), the process by which stationary epithelial cells transform into motile, invasive cells capable of seeding metastases. Identifying such molecular sensors offers a new window into how tumors integrate mechanical and metabolic signals to shift toward more dangerous states.

Strengthening this effort is the contribution of emerging biomedical engineering researchers such as Toheeb E. Alao, an expert researcher and scholar at the New Jersey Institute of Technology whose work centers on mechanometabolism and glycocalyx remodeling in breast cancer. His training includes advanced techniques such as polyacrylamide hydrogel fabrication, RNA-seq analysis, CRISPR–Cas9 editing, lentiviral overexpression, confocal microscopy, and mechano-responsive glycosylation profiling. Alao also co-authored a 2024 peer-reviewed article on the mechanics of cancer sialylation (Frontiers in Oncology), providing scientific context for why sialylation is increasingly viewed as a driver of tumor aggressiveness. His experience with fast cloning, glycoengineering, and bioinformatics analysis helps support the experimental rigor required for this highly interdisciplinary project.

To test the hypothesis that ST6GALNAC4 and ST6GALNAC6 orchestrate EMT in response to mechanical stress, the team will combine CRISPR-Cas9 genetic manipulation with molecular imaging, stable-isotope metabolic tracing, immune-cell cytotoxicity assays, and three-dimensional migration studies. Advanced methods such as atomic force microscopy will quantify how cells experience mechanical forces, while in-vivo mouse models will help determine whether altering these mechanoresponsive enzymes changes metastatic potential.

This innovative research holds significant relevance for the United States and the rest of the world, where breast cancer remains the most commonly diagnosed cancer in women and a leading cause of cancer-related mortality. By creating physiologically grounded models that more accurately represent the biochemical and mechanical landscape of real tumors, the study aligns with U.S. priorities in precision medicine, translational oncology, and the development of next-generation cancer therapeutics.

The U.S. National Institutes of Health and National Cancer Institute have increasingly emphasized the importance of tumor biomechanics, microenvironment engineering, and metabolic regulation as frontiers for improving cancer outcomes. Understanding how mechanical and metabolic cues cooperate may deepen national capacity to predict metastasis, develop more targeted therapies, and reduce treatment resistance—challenges that cost the U.S. billions in healthcare expenditures annually.

If successful, the research could reveal why some tumors undergo rapid malignant transformation while others progress more slowly. It may also identify new therapeutic targets at the intersection of mechanics, metabolism, and glycobiology—an area where expert scientists like Alao are helping build a new generation of cancer research frameworks. As knowledge of mechano-metabolic crosstalk expands, it could reshape clinical approaches to risk stratification and pave the way for innovative treatments that modify the tumor’s physical and metabolic environment to slow or prevent metastasis.